CBD Drug Interactions – Complete Warning List 2026

Cannabidiol is regularly used by approximately 14% adult Poles, and among them, more than one third also take prescription drugs (CBOS, 2024). This is a real population at risk for clinically significant pharmacokinetic interactions. CBD inhibits multiple hepatic cytochrome P450 isoenzymes, modifying drug concentrations ranging from warfarin to clobazam and statins.

The mechanism is well described in the literature. CBD is a moderate to strong inhibitor of CYP3A4, CYP2C19, and CYP2C9 (Epidiolex Prescribing Information, FDA, 2018). These three enzymes are responsible for the breakdown of approximately 75% of all oral drugs (Stout & Cimino, Drug Metabolism Reviews, 2014). The scale of potential interactions is therefore wide.

This guide describes specific classes of medications that require caution or active monitoring when combining with CBD. This is not a DIY article. Cannabidiol is not a neutral supplement when compared to warfarin, clobazam, tacrolimus, or benzodiazepines. Any decision regarding combinations rests with the treating physician and clinical pharmacist.

KEY INFORMATION
– CBD inhibits CYP3A4, CYP2C19 and CYP2C9, i.e. the isoenzymes responsible for the metabolism of 75% prescription drugs (Stout & Cimino, 2014).
– The red list includes drugs with a narrow therapeutic window: warfarin, clobazam, valproate, tacrolimus, cyclosporine, atorvastatin, simvastatin.
– Clobazam: increase in N-desmethyl metabolite concentration by 300-500% (Devinsky, NEJM, 2017).
– Grapefruit juice acts similarly to CBD on CYP3A4. Combining them increases the risk of interactions (FDA Consumer Update, 2017).
– Always consult a pharmacist or doctor before adding CBD to your regular medication regimen.

How does CBD inhibit cytochrome P450 and why does it matter?

CBD is a clinically significant inhibitor of the three major CYP450 isoenzymes: CYP3A4, CYP2C19 and CYP2C9 (Epidiolex Prescribing Information, FDA, 2018). These enzymes are involved in the breakdown of about three-quarters of oral medications (Stout & Cimino, Drug Metabolism Reviews, 2014). The result: drug concentrations increase and clinical effects may change unpredictably.

Cytochrome P450 is a family of liver enzymes responsible for the biotransformation of xenobiotics. Most oral medications undergo what's known as first-pass metabolism, in which CYP450 oxidizes, hydroxylates, or demethylates molecules. The transformed products are more easily excreted in urine or bile. This is a biochemical "detoxification factory.".

When CBD blocks the activity of a specific isoenzyme, its substrate drugs remain in circulation longer. The increase in AUC (area under the concentration curve) can range from 30% to as much as 500% depending on the drug and CBD dose (Brown & Winterstein, Journal of Clinical Medicine, 2019). For drugs with a narrow therapeutic window, this is a clinically significant change.

Which isoenzymes does CBD inhibit most strongly?

CYP3A4 is the most abundant isoenzyme in human liver. It metabolizes approximately 50% of oral medications, including statins (atorvastatin, simvastatin), benzodiazepines (alprazolam, midazolam), tacrolimus, cyclosporine, calcium channel blockers (amlodipine, diltiazem), and most protease inhibitors. CBD is a moderate CYP3A4 inhibitor in vitro and in vivo.

CYP2C19 metabolizes clobazam, omeprazole, clopidogrel, and citalopram. CBD is a potent inhibitor of this isoenzyme. This explains the dramatic increase in N-desmethylclobazam concentrations described in Devinsky's studies (NEJM, 2017 and 2018). Genetic polymorphism of CYP2C19 (poor metabolizers) further complicates the picture.

CYP2C9 metabolizes warfarin, phenytoin, nonsteroidal anti-inflammatory drugs (ibuprofen, naproxen), and losartan. CBD inhibits this pathway moderately, but for S-warfarin (the more potent enantiomer), the consequences are clinically important, and an increase in INR above 4.0 has been observed in reported cases (Grayson, Epilepsy & Behavior Case Reports, 2018).

Induction or inhibition – which prevails?

Most clinical studies report inhibition, or increased concentrations of drugs metabolized by CBD. However, there are reports of induction of certain pathways with long-term use of high doses of CBD. This effect varies depending on individual genetics, body weight, and duration of therapy.

There's one practical consequence: in the first few weeks of combining CBD with medications, we expect their concentrations to increase. In the long term, the picture may change. Therefore, clinical and laboratory monitoring remains ongoing throughout the co-therapy period, not just at the beginning.

CBD inhibits the CYP3A4, CYP2C19, and CYP2C9 isoenzymes, which are responsible for the metabolism of approximately 75% of oral drugs. The increase in AUC ranges from 30% to 500% depending on the substrate and the dose of cannabidiol (Stout & Cimino, Drug Metabolism Reviews, 2014; FDA Epidiolex Prescribing Information, 2018).

Red list – drugs with a narrow therapeutic window

The red list includes drugs for which even a small change in serum concentration translates into serious clinical consequences. This includes, among others, warfarin (INR), clobazam, valproate, tacrolimus, cyclosporine, lithium, and some statins. For these drugs, co-therapy with CBD requires active monitoring, not just symptom monitoring (EMA, 2023).

Why is a "narrow therapeutic window" a key concept? It's the difference between an effective dose and a toxic dose. The narrower the window, the less tolerance there is to changes in concentration. For warfarin, the INR should be between 2.0 and 3.0 (or 2.5 and 3.5 for some indications). Values above 4.0 significantly increase the risk of intracranial bleeding.

The red list does not constitute an absolute prohibition. It means that the decision is made by a physician, laboratory parameters are monitored, and the drug dose may require adjustment. Patients cannot independently assess the risk. In this context, cannabidiol is not a dietary supplement, but an active pharmacokinetic modulator.

Narrow therapeutic window criteria

The FDA and EMA use similar criteria. A drug has a narrow therapeutic window if the difference between the effective and toxic dose is less than two-fold, and small changes in concentration (below 25%) lead to loss of efficacy or toxic symptoms. This category includes cardiology, immunosuppressive, antiepileptic, and some psychotropic drugs.

In daily pharmaceutical practice, each such drug has a monitoring protocol. For warfarin, this is an INR. For cyclosporine and tacrolimus, it's a blood concentration test. For lithium, it's lythemia. For valproate, it's liver function tests and valproic acid concentration. CBD, as a modulator, requires inclusion in these protocols, along with other modifying factors.

Red flags for immediate response

Regardless of laboratory testing, there are symptoms that require immediate medical consultation. With CBD and warfarin co-therapy: bleeding gums, hematuria, tarry stools, subcutaneous hematomas. With clobazam: increased drowsiness, slurred speech, ataxia. With statins: muscle pain, dark urine, weakness. With tacrolimus: tremors, increased blood pressure, headaches.

These symptoms do not always indicate an interaction with CBD, but if used concurrently, they require evaluation. Your doctor will order appropriate tests (INR, drug concentrations, liver function tests, CK), based on which they will decide whether to adjust the dose or discontinue one of the medications. Do not modify the regimen on your own.

Anticoagulants and CBD – why does INR rise?

Warfarin is a classic example of a drug with a narrow therapeutic window. CBD inhibits CYP2C9 and CYP3A4, which metabolize both enantiomers of warfarin (S- and R-). In the reported case of a 39-year-old man, the INR increased from 2.5 to 4.7 after the introduction of CBD and required a reduction in the warfarin dose by 30% (Grayson, Epilepsy & Behavior Case Reports, 2018).

The mechanism is well understood. S-warfarin, the more potent enantiomer, is metabolized primarily by CYP2C9. Inhibition of this isoenzyme by CBD slows its degradation, increases serum concentrations, and prolongs the anticoagulant effect. This results in an increased INR and a risk of bleeding, including potentially life-threatening intracranial hemorrhages.

Newer anticoagulants (DOACs: dabigatran, rivaroxaban, apixaban, edoxaban) are also subject to interactions. Rivaroxaban and apixaban are substrates of CYP3A4 and P-glycoprotein. CBD inhibits both pathways. The lack of routine drug level monitoring complicates the detection of interactions, so patients taking DOACs and CBD require close monitoring for bleeding symptoms.

INR monitoring practice

Typically, the INR is measured every 4-6 weeks during stable warfarin therapy. After initiating CBD, your doctor will order monitoring every 7-14 days for the first 6 weeks. If the INR stabilizes, the frequency decreases. Any change in CBD dose or discontinuation of therapy warrants additional monitoring.

A patient keeping an "INR diary" helps the doctor make decisions. Record the date of the measurement, the INR value, the warfarin dose, the CBD dose, and any new medications or supplements. It sounds pedantic, but for people with prosthetic valves, atrial fibrillation, or those recovering from a pulmonary embolism, it's a lifesaving standard.

Heparin and fondaparinux

Low molecular weight heparins (enoxaparin, dalteparin) and fondaparinux are not metabolized by CYP450. Pharmacokinetic interactions with CBD are therefore minimal. However, the risk remains at the pharmacodynamic level, as CBD may have a minor effect on platelet aggregation (Brown & Winterstein, Journal of Clinical Medicine, 2019).

In clinical practice, heparin is used for short-term treatment, in hospital settings or after procedures. CBD is usually not continued in these cases. If a patient is taking enoxaparin long-term (e.g., during pregnancy or with recurrent thrombosis), it is advisable to inform their doctor about CBD supplementation.

Combining CBD with warfarin may increase the INR above 4.0 and require a reduction in the warfarin dose by 25-30%. The mechanism is inhibition of CYP2C9, which metabolizes S-warfarin (Grayson, Epilepsy & Behavior Case Reports, 2018). Any change in CBD dose requires an additional INR test within 7-14 days.

Antiepileptic drugs – clobazam, valproate, clozapine

Clobazam and valproate are classic examples of antiepileptic drugs for which co-therapy with CBD is well-studied. In the Devinsky 2017 study on Dravet syndrome, the increase in N-desmethylclobazam (the active metabolite) concentration was 300-500lTP3T in children using CBD (Devinsky, New England Journal of Medicine, 2017).

The mechanism is clear. Clobazam undergoes N-demethylation to N-desmethylclobazam by CYP3A4. N-desmethylclobazam is then hydroxylated by CYP2C19. CBD inhibits CYP2C19, so N-desmethylclobazam accumulates in serum. This results in increased sedation, ataxia, and sometimes requires a clobazam dose reduction by up to 501 TP3T.

Valproate presents another problem. CBD and valproate act synergistically for hepatotoxicity. In the Devinsky 2018 study of Lennox-Gastaut syndrome, approximately 20% children combining both drugs experienced increases in ALT and AST above three times the normal range (Epidiolex Prescribing Information, FDA, 2018).

Liver function test monitoring protocol

The FDA requires Epidiolex (purified pharmaceutical CBD) prescriptions to measure ALT, AST, and bilirubin before starting treatment, after 1, 3, and 6 months, and whenever the dose is changed. When co-administered with valproate, testing is recommended every 4 weeks in the first quarter. An increase in transaminases above 3x the norm or bilirubin above 2x the norm is cause for reduction or discontinuation (FDA, 2018).

In Polish practice, epilepsy patients taking valproate rarely use CBD without their neurologist's knowledge. However, the situation changes when CBD is presented as a "natural sleep supplement" or "mood support" and the patient doesn't inform their doctor. Hence, the importance of an open conversation with a neurologist before making any modifications to their supplementation.

Carbamazepine and phenytoin

Carbamazepine and phenytoin are classic inducers of CYP450, including CYP3A4. Co-therapy with CBD produces a bidirectional effect. CBD inhibits CYP3A4, but carbamazepine induces the same isoenzyme, which may lower CBD levels and reduce its anticonvulsant effect. Conversely, changes in carbamazepine concentrations remain modest.

Phenytoin is a substrate of CYP2C9 and CYP2C19. Inhibition by CBD may increase its concentration and lead to toxicity (nystagmus, ataxia, disorientation). Serum phenytoin concentrations should be within a narrow range of 10-20 mg/L. Each administration of CBD should result in additional concentration determinations after 2-4 weeks.

Briwarcetam, lacosamide, levothyracetam

Newer antiepileptic drugs have a different profile. Brivarcetam and lacosamide are primarily metabolized by CYP2C19, so CBD may increase their concentrations. Levetiracetam is excreted unchanged by the kidneys, so interaction with CBD is minimal. This makes it a relatively safe option for combined epilepsy therapy with CBD.

The decision to choose a specific antiepileptic drug always rests with the neurologist. CBD is not a "safe additive," but an active modulator of the regimen, which must be considered in every recommendation. Patients requesting CBD supplementation must be given a clear answer.

Unique observation: In Polish neurological practice, awareness of CBD-clobazam interactions is growing thanks to the registration of Epidiolex in the EU (2019). Despite this, many parents of children with drug-resistant epilepsy provide "additional" CBD oil alongside Epidiolex therapy, believing that "more of the same" will enhance the effect. This is a mistake. The total CBD dose must be included in the calculation of CYP inhibition, as pharmaceutical and supplemental sources are pharmacokinetic additive.

Statins and CBD – Risk of Myopathy

Atorvastatin and simvastatin are metabolized primarily by CYP3A4. Inhibition of this isoenzyme by CBD may increase their serum concentrations by 30-1001TP3A4, increasing the risk of myopathy and rhabdomyolysis (Brown & Winterstein, Journal of Clinical Medicine, 2019). Pravastatin and rosuvastatin are less dependent on CYP3A4, so the risk of interaction with CBD is significantly lower.

Statin-induced myopathy manifests as muscle pain, weakness, and sometimes dark urine. Rhabdomyolysis is a more severe form, leading to the release of myoglobin and acute kidney injury. In the Polish population over 60, where approximately 40% patients use statins, awareness of the risk of interactions with CBD is low.

A practical recommendation: A patient on atorvastatin or simvastatin who wishes to switch to CBD should discuss the change with their family doctor or cardiologist. Options include switching to pravastatin or rosuvastatin, reducing the statin dose, or discontinuing CBD. The decision is made by the physician based on the patient's cardiovascular risk profile.

What to do when your muscles hurt?

If a patient taking CBD and a statin reports new muscle pain, the doctor will order a creatine kinase (CK) test. CK values above 5x the reference range require discontinuation of the statin and reassessment after 4-6 weeks. CBD should also be discontinued at this time to facilitate identification of the underlying cause. Reintroduction to therapy should be gradual, once the parameters have normalized.

Some patients report muscle pain as a placebo effect or a side effect of stress. A doctor's clinical assessment helps distinguish true myopathy from symptoms unrelated to medication. Stopping a statin without consulting a doctor can have serious cardiac consequences, so it's always important to discuss this with your doctor.

Other lipid-lowering drugs

Ezetimibe is metabolized primarily by glucuronidation, not by CYP450. Interactions with CBD are minimal. Fibrates (fenofibrate, gemfibrozil) are CYP3A4 substrates, so there is a theoretical risk of interaction, but clinical data are limited. PCSK9 inhibitors (alirocumab, evolocumab) are administered subcutaneously and are not subject to CYP450 metabolism.

The choice of alternative lipid-lowering medications is always a decision made by a specialist. Patients interested in CBD should discuss this preference during a cardiology consultation to ensure it is considered when selecting a treatment. An open dialogue facilitates the safe combination of both strategies.

Benzodiazepines and opioids – CNS depression

CBD and benzodiazepines depress the central nervous system through different mechanisms. Benzodiazepines enhance the effects of GABA, while CBD modulates 5-HT1A and GPR55 receptors and indirectly increases anandamide levels. Combining both leads to increased sedation, impaired coordination, and rarely, respiratory depression (Brown & Winterstein, Journal of Clinical Medicine, 2019).

Additionally, CBD inhibits CYP3A4 and CYP2C19, increasing concentrations of benzodiazepines metabolized via these pathways. Alprazolam, midazolam, and triazolam are CYP3A4 substrates. Diazepam is metabolized by CYP3A4 and CYP2C19. Lorazepam and oxazepam are glucuronidated, so the pharmacokinetic interaction is minimal, but the pharmacodynamic risk remains.

Practical implications: Patients chronically using benzodiazepines (e.g., for generalized anxiety or insomnia) and considering CBD should speak with a psychiatrist. CBD is not a safe "sleep aid" when benzodiazepine derivatives are involved. The risk of oversedation increases, particularly in older adults and drivers.

Opioids and the Risk of Respiratory Depression

Opioids (morphine, oxycodone, fentanyl, tramadol) depress the respiratory center in the brainstem. CBD has no significant effect on this center on its own, but in combination with opioids it may enhance sedation and indirectly increase the risk of slowed breathing. Tramadol is also a substrate of CYP2D6 and CYP3A4, so there is also a pharmacokinetic risk.

Cancer patients using opioids for chronic pain often consider CBD as an adjunct. This decision should be made by their treating physician (oncologist or palliative care specialist). Appropriate dosing of both substances, monitoring sedation, and assessing breathing at night are key elements of safe co-therapy.

Z-drugs – zopiclone, zolpidem

Zopiclone and zolpidem are popular for insomnia, acting on the GABA-A receptor similarly to benzodiazepines. CBD may enhance their sedative effects. Zolpidem is metabolized by CYP3A4 (at 60%) and CYP2C9, so increased serum concentrations are expected. Effects: excessive morning sleepiness and risk of falls, particularly in the elderly.

Combining CBD with Z-drugs is not strictly prohibited, but requires caution and typically a dose reduction of the Z-drug by 25-501 TP3T. For long-term co-therapy, it's worth considering alternative sleep improvement strategies, including sleep hygiene, CBT-I therapy, and possibly CBD monotherapy under medical supervision.

SSRIs and SNRIs – risk of serotonin syndrome?

CBD, a 5-HT1A pathway modulator, and SSRIs (sertraline, escitalopram, fluoxetine) increase serotonergic activity. There is a theoretical risk of serotonin syndrome, but clinical data to date do not support a high incidence. A more significant concern is the pharmacokinetic interaction of CBD with SSRI metabolism via CYP2C19 and CYP3A4 (PMC, 2019).

Citalopram and escitalopram are metabolized primarily by CYP2C19. Inhibition by CBD may increase their concentrations. This may result in prolongation of the QT interval on the ECG, which is important for cardiac patients. Sertraline is a substrate of CYP2D6 and CYP2C19, while fluoxetine primarily targets CYP2D6. Therefore, interaction profiles differ among the SSRIs.

SNRIs (venlafaxine, duloxetine) are metabolized by CYP2D6 and CYP3A4. The effect of CBD is variable and depends on the patient's CYP2D6 polymorphism. CYP2D6 poor metabolizers may have significantly higher venlafaxine concentrations when co-administered with CBD than extensive metabolizers.

Tricyclic antidepressants

Amitriptyline, nortriptyline, and clomipramine are metabolized by CYP2D6, CYP3A4, and CYP2C19. CBD may significantly increase their concentrations. Tricyclic antidepressants have a narrow therapeutic window and a risk of cardiotoxicity (QT prolongation, arrhythmias). Co-administration with CBD requires ECG monitoring and, if necessary, measurement of drug concentrations in the blood.

In Polish practice, TCAs are used less frequently than before, more often for neuropathic pain (amitriptyline, low doses) than for depression. A patient with diabetic polyneuropathy using amitriptyline and considering CBD for the same pain should consult a neurologist or diabetologist before initiating supplementation.

MAO inhibitors and the risk of interactions

Monoamine oxidase inhibitors (moclobemide, selegiline) are rarely used in Poland, but when they do occur, they require special caution. CBD does not exhibit strong pro-serotoninergic effects, so the direct risk of MAOI-related serotonin syndrome is low. You should still inform your doctor about CBD supplementation whenever you change your antidepressant medication.

Immunosuppressants – tacrolimus, cyclosporine, sirolimus

Tacrolimus, cyclosporine, and sirolimus are among the drugs with the narrowest therapeutic windows. They are metabolized primarily by CYP3A4 and are substrates of P-glycoprotein. CBD inhibits both pathways. A case report of a kidney transplant patient showed an increase in tacrolimus concentration from 6.5 to 12.3 ng/ml after the addition of CBD 30 mg daily (Leino et al., American Journal of Transplantation, 2019).

The consequences of interactions are serious. High concentrations of tacrolimus lead to nephrotoxicity, neurotoxicity (tremors, headaches, confusion), hyperglycemia, and hypertension. Cyclosporine at toxic concentrations can cause kidney damage, hypertension, hypertrichosis, and gingival hyperplasia. Sirolimus also exerts a more concentration-dependent effect on the immune system.

Organ transplant patients take immunosuppressants for life. The introduction of CBD requires consultation with a transplant specialist. Transplant doctors typically advise against additional CYP3A4-modulating supplements, including CBD, St. John's wort, and grapefruit. Exceptions are rare and require intensive monitoring of concentrations.

Mycophenolate mofetil and azathioprine

Mycophenolate mofetil is metabolized by glucuronyl transferases (UGTs), not CYP450. Therefore, pharmacokinetic interactions with CBD are minimal. Azathioprine is metabolized by thiopurine-S-methyltransferase (TPMT) and xanthine oxidase. CBD does not significantly affect these pathways. Therefore, these drugs are relatively safe when combined with CBD, although clinical data are limited.

Nevertheless, every immunosuppressed patient should inform their physician about CBD supplementation. The overall health of the immune system, the risk of infection, and pharmacodynamic interactions (e.g., with corticosteroids) require assessment. Open communication with the transplant surgeon is the foundation of safe co-therapy.

Beta-blockers and cardiology medications

Metoprolol is metabolized by CYP2D6, while propranolol is metabolized by CYP1A2 and CYP2D6. CBD weakly inhibits CYP2D6 and CYP1A2, so the direct pharmacokinetic interaction is moderate. The potential additive effect on blood pressure is more significant. CBD at higher doses may lower blood pressure, which, when combined with a beta-blocker, may lead to bradycardia and hypotension.

Bisoprolol is primarily excreted unchanged by the kidneys (50%) and metabolized by CYP3A4 (50%). CBD may moderately increase its concentration. Carvedilol is a substrate of CYP2D6 and CYP2C9. Atenolol is almost entirely excreted by the kidneys, so interaction with CBD is minimal. The choice of a specific beta-blocker for a patient taking CBD should be discussed with a cardiologist.

Calcium channel blockers

Amlodipine, diltiazem, and verapamil are metabolized primarily by CYP3A4. CBD inhibits this isoenzyme, so there's a risk of elevated drug concentrations. This can result in excessive hypotension, peripheral edema, and constipation. Diltiazem and verapamil are also CYP3A4 inhibitors themselves, creating a complex picture of interactions.

A patient with hypertension treated with amlodipine who wishes to introduce CBD should monitor their blood pressure daily for the first 2-4 weeks. Any need to reduce the amlodipine dose is at the discretion of their family doctor or cardiologist. Individual adjustments are not acceptable, as uncontrolled hypertension increases the risk of stroke.

ACE inhibitors and sartans

Enalapril, ramipril, and perindopril are prodrugs activated by hepatic esterases. CBD does not significantly affect this pathway. Sartans (losartan, valsartan, telmisartan) are substrates of CYP2C9 (losartan) or, to a lesser extent, CYP3A4 (valsartan). Inhibition by CBD may moderately increase their concentrations, but clinically significant interactions are rarely reported.

Proton pump inhibitors and gastrointestinal medications

Omeprazole, lansoprazole, and pantoprazole are primarily metabolized by CYP2C19. CBD inhibition of this isoenzyme can elevate their concentrations, which is usually clinically tolerable (PPIs have a wide therapeutic window). A more significant concern is the indirect effect: PPIs reduce gastric acidity, which can impact the bioavailability of other medications, potentially including oral CBD itself.

Esomeprazole, the S-enantiomer of omeprazole, has a narrower safety window and is more likely to cause interactions. Clopidogrel is activated by CYP2C19, so cardiologists advise against coadministration of omeprazole with clopidogrel. CBD also inhibits CYP2C19, so for post-myocardial infarction patients taking clopidogrel and CBD, there is a theoretical risk of reduced antiplatelet efficacy, although clinical data are limited.

H2 receptor antagonists

Ranitidine, famotidine, and cimetidine are used less frequently than PPIs, but are still present. Cimetidine itself is a moderate CYP450 inhibitor, so coadministration with CBD does not significantly exacerbate the metabolic situation. Famotidine has minimal effects on CYP450 and is relatively safe in combination with CBD. In practice, most patients with reflux are treated with PPIs, not H2 blockers.

What to do if you take medication and are thinking about CBD?

The first step is to talk to a pharmacist or your doctor, not the internet. The Polish healthcare system allows for pharmaceutical consultations in pharmacies (from 2022), which are dedicated to precisely these kinds of questions (Ministry of Health, 2024). A pharmaceutical consultation costs approximately PLN 30-50 and provides access to a professional assessment of the risk of interactions.

The second step is to compile a complete list of medications and supplements. Enter each substance, dosage, frequency, and indication. Bring this list to your appointment. Your doctor or pharmacist will use this list to assess the risk of interactions with CBD and recommend further action. Without a complete list, an assessment is impossible.

The third step is a genuine willingness to accept rejection. Sometimes the appropriate recommendation is "do not combine." A transplant patient on tacrolimus, a heart attack patient on warfarin, a child with epilepsy on clobazam – these are groups for whom CBD is often not a good choice. Accepting such a recommendation is a sign of common sense, not failure.

A practical path to pharmaceutical consultation

Step 1: Schedule a pharmaceutical consultation at a pharmacy. A referral from your primary care physician or self-referral is required. Duration: 30-45 minutes. Step 2: Prepare a medication list, recent test results (INR, liver function tests, creatinine, lipid profile), and a description of any chronic conditions. Step 3: Discuss the purpose of CBD supplementation with your pharmacist (sleep, anxiety, pain, recovery).

Step 4: The pharmacist will analyze interactions with each drug on the list using the Lexicomp, Micromedex, or the national KAMSOFT drug interaction database. Step 5: You will receive a written recommendation (green light, caution with monitoring, no recommendation). Step 6: If the recommendation is positive, discuss the starting dose, schedule, and monitoring parameters.

Why "Hemp Oil" Doesn't Mean "Neutral"„

CBD is not aspirin or vitamin C. It is an active pharmacokinetic modulator whose clinical effects are well documented in the literature. The tradition of a "natural supplement" does not exempt us from assessing interactions. Warfarin also has a "natural" origin (from clover) and requires close monitoring.

The marketing language of "hemp oil for health" is misleading if it ignores the pharmacokinetic aspect. Producers of high-quality CBD oils are increasingly including information on their packaging about the need for consultation when co-administering medications. This is good market practice and should be supported by informed purchasing choices.

CBD Drug Interaction Summary Table

The table below summarizes the most important data on CBD interactions in one place. Each row includes the drug or class name, the mechanism of interaction, the most important clinical signs indicating the need for a response, and the recommended course of action. The table is for informational purposes only and does not replace consultation with a pharmacist or physician.

Drug or class	Interaction mechanism	Clinical signal	Procedure
Warfarin, acenocoumarol	CYP2C9 inhibition (S-warfarin)	INR increase above 4.0, bleeding	INR monitoring every 7-14 days, dose adjustment by the physician
Clobazam	CYP2C19 inhibition, N-desmethyl accumulation	Drowsiness, ataxia, slurred speech	Clobazam reduction by 25-50% under the supervision of a neurologist
Valproate	Hepatotoxic synergy	Increase in ALT/AST above 3x normal	Liver function tests every 4 weeks in the 1st quarter
Tacrolimus, cyclosporine	Inhibition of CYP3A4 and P-gp	Increased concentrations, nephrotoxicity, tremors	Monitoring of concentrations, decision of the transplantologist
Atorvastatin, simvastatin	CYP3A4 inhibition	Muscle pain, dark urine, increased CK	Consider switching to pravastatin or rosuvastatin
Benzodiazepines (alprazolam, midazolam)	CYP3A4 inhibition + additive sedation	Excessive sleepiness, impaired coordination	Benzodiazepine dose reduction, psychiatric follow-up
Opioids (oxycodone, tramadol)	Additive CNS depression, partially CYP3A4	Excessive sedation, slowed breathing	Consultation with a pain management physician
SSRIs (citalopram, escitalopram)	CYP2C19 inhibition	QT prolongation, nausea, tremors	ECG at higher doses, psychiatric follow-up
Clopidogrel	CYP2C19 inhibition (prodrug activation)	Potential reduction in effectiveness	Consultation with a cardiologist
Amlodipine, diltiazem	CYP3A4 inhibition	Hypotension, edema, dizziness	Pressure measurements, dose reduction
Omeprazole, esomeprazole	CYP2C19 inhibition	Usually well tolerated	Standard monitoring
Phenytoin, carbamazepine	Complex (inhibition vs induction)	Change in concentrations, seizures or toxicity	Determine concentrations every 2-4 weeks

From the Bucha editorial office: In our practice, the most common question is "can I take CBD with high blood pressure medications." The second most common category is sleep medications and anti-anxiety medications. The third category is cardiac medications (warfarin, statins). In each of these cases, we refer customers to a pharmacist or doctor, without exception. We do not sell CBD as a "natural drug replacement"—we sell it as a supplement that requires informed assessment when used in combination therapy.

A practical consultation path – step by step

An informed decision to combine CBD with medications requires a consultation process that includes at least five stages: medication list, pharmacist consultation, laboratory test results, medical decision, and monitoring. Each stage has its own function, and skipping any increases the risk of unexpected clinical effects (EMA, 2023).

Step 1: Collecting information about medications

List all prescription medications, over-the-counter (OTC) medications, dietary supplements, and herbs. Include dosages, frequency, and times of use. Indicate when you started each medication. If you recently changed your medication, describe the reason. Your doctor or pharmacist will use this list to identify potential interactions with CBD.

Important: Remember to include periodic medications (e.g., ibuprofen for headaches, omeprazole for heartburn), as they also participate in CYP450 metabolism. Even grapefruit juice consumed daily affects CYP3A4 and should be included in the diet. A complete picture allows for an accurate assessment.

Step 2: Pharmacist or doctor consultation

A pharmacist in a pharmacy can provide consultations under the Pharmaceutical Care (PMC) program. A primary care physician is qualified to assess simpler interactions. In complex cases (immunosuppression, anticoagulants, epilepsy), consultation with a specialist is required: cardiologist, hepatologist, neurologist, or transplantologist.

A well-prepared patient saves the professional time. Ask specific questions like, "Can I combine 25 mg of CBD daily with 20 mg of atorvastatin?" rather than general questions like, "Is CBD safe?" Specific questions elicit specific answers.

Stage 3: baseline research

Before introducing CBD, it's important to have current (from the last three months) results of basic tests: complete blood count, ALT, AST, bilirubin, creatinine, lipid profile. If you're taking warfarin: current INR. If you're taking clobazam or phenytoin: current drug concentrations. If you're taking tacrolimus or cyclosporine: current drug concentrations. These results serve as a "starting point" for comparison.

After initiating CBD, your doctor will order repeat tests after 4-6 weeks. Comparing the "before" and "after" results allows you to assess whether any changes suggest an interaction have occurred. Without a baseline, interpretation is difficult because we don't know what constitutes "normal" for a given patient.

Step 4: Medical Decision and Protocol

The decision "yes/no/with caution" rests with the physician. If the decision is "yes with monitoring," the physician will determine the protocol: starting CBD dose, schedule for escalation, parameters to be monitored, and frequency of follow-up. The patient should receive this information in writing or as a prescription.

The decision to "no" should be respected. The patient has the right to ask for reasons, but ultimately, medical responsibility rests with the doctor. Attempting to bypass recommendations (buying CBD without the doctor's knowledge) increases risk and makes it more difficult to identify problems when they arise.

Stage 5: Monitoring and Control

During CBD-medication therapy, the patient monitors symptoms (sedation, bleeding, muscle pain, tremors, blood pressure changes). The doctor will order periodic tests. Any significant change in well-being requires medical attention, not necessarily discontinuation of CBD on your own. Gradual modifications are safer than sudden changes.

After 3-6 months of stable co-therapy, the frequency of monitoring may decrease. However, this requires maintaining awareness that each new drug introduced into the regimen (e.g., an antibiotic for an infection) may alter the pharmacokinetic profile. Each change in therapy requires a new assessment of interactions.

Grapefruit juice, St. John's wort, and other CYP450 modifiers

Grapefruit juice contains furanocoumarins, which inhibit CYP3A4 similarly to CBD. Consuming 200 ml of juice may increase the concentration of statins, calcium channel blockers, and some immunosuppressants by 70-200% (FDA Consumer Update, 2017). Combining CBD and grapefruit may have a synergistic inhibitory effect.

St. John's wort is a strong inducer of CYP3A4 and CYP2C9. It has the opposite effect to CBD and grapefruit, lowering the concentrations of drugs metabolized by these enzymes. Coadministration of CBD and St. John's wort may produce a net effect close to zero on a specific drug, but the effect is unpredictable and changes over time. Not recommended.

Bitter orange (Sevilla orange) has a similar effect to grapefruit. Pomegranate has a weaker, but still noticeable, inhibitory effect on CYP3A4. Some herbal supplements (echinacea, ginkgo biloba, ginkgo biloba) affect CYP450 in ways that are difficult to predict. Each of these factors is worth discussing with a pharmacist when consulting about CBD.

Alcohol and CBD

Alcohol is a CYP2E1 inducer and can induce CYP3A4 with chronic consumption. The effect is minimal with occasional use. A more significant concern is the additive sedation – CBD and alcohol both depress the CNS, which increases drowsiness and coordination problems. Combining an evening dose of CBD with alcohol is not recommended.

Coffee and caffeine

Coffee contains compounds that simultaneously induce and inhibit various CYP450 isoenzymes. The net effect is moderate. Combining CBD with coffee is common and does not generate significant clinical interactions. Some CBD users even report improved caffeine tolerance when used concomitantly, but these are subjective observations and not confirmed by research.

Warning signs – when to contact a doctor immediately?

Certain symptoms during CBD co-therapy with medications require immediate medical consultation, rather than waiting for a scheduled appointment. Bleeding gums, hematuria, tarry stools, and subcutaneous hematomas occurring without trauma are symptoms of excessive anticoagulation requiring urgent INR testing and medical evaluation. Intracranial bleeding is a life-threatening condition.

Severe drowsiness that interferes with normal functioning, confusion, slurred speech, and ataxia may indicate benzodiazepine, clobazam, or opioid toxicity enhanced by CBD. Contact your doctor or visit an emergency room. Do not drive if you experience this condition. Muscle pain, dark urine, and weakness may indicate possible statin-induced myopathy, requiring CK and creatinine testing.

Tremors, elevated blood pressure, and headaches in a transplant patient—possible tacrolimus or cyclosporine toxicity. Urgent drug concentration testing and consultation with a transplant specialist are required. A marked deterioration in epilepsy control (recurrence of seizures after a period of remission)—possible interaction with an antiepileptic drug, requiring consultation with a neurologist.

Conditions that do not require urgent contact

Mild drowsiness in the morning after an evening dose of CBD, dry mouth, increased appetite, and mild fatigue—these are typical side effects of CBD in themselves, and don't always indicate an interaction. These can be monitored and discussed at a scheduled follow-up appointment. If they persist for more than two weeks or worsen, it's worth consulting a doctor sooner.

A gradual decrease in CBD's effectiveness after prolonged use may indicate tolerance and require a 1-2-week break ("CBD vacation"). This is not a drug interaction, but rather the body's adaptation. It's worth discussing a break strategy with your pharmacist, especially if you're using CBD alongside chronic medications.

Summary – Safe Use of CBD with Medications

CBD is an active cytochrome P450 modulator, not a neutral supplement. It inhibits CYP3A4, CYP2C19, and CYP2C9 isoenzymes responsible for the metabolism of 75% oral medications. This may result in clinically significant interactions, particularly with drugs with a narrow therapeutic window: warfarin, clobazam, valproate, tacrolimus, statins, and benzodiazepines.

Informed use requires consultation with a pharmacist or treating physician, compiling a complete medication list, monitoring laboratory parameters, and observing symptoms. This is not a "DIY" decision that the patient makes on their own. The Polish healthcare system offers pharmaceutical consultations for a small fee—an investment in safety.

CBD has real therapeutic potential, but its value depends on the patient's pharmacological context. For a healthy individual not taking medication, the risk is minimal. For a patient on polypharmacy, it requires individual assessment. A starting dosage (5-10 mg daily) and gradual escalation minimize the risk of sudden pharmacokinetic changes.

Remember these three rules: medication list, pharmacist consultation, and monitoring. Any new therapy introduced while using CBD requires reassessment of interactions. Any new symptoms (drowsiness, bleeding, muscle pain) require medical attention. Safety is not optional—it's the standard.

Frequently Asked Questions

Does CBD interact with all medications?

No. CBD primarily affects drugs metabolized by the CYP3A4, CYP2C19, and CYP2C9 isoenzymes, which together account for the breakdown of approximately 75% of all prescription drugs (Stout & Cimino, Drug Metabolism Reviews, 2014). The highest risk applies to drugs with a narrow therapeutic window: warfarin, clobazam, valproate, tacrolimus, and some statins. Always consult your pharmacist or doctor.

Can I take CBD with warfarin?

Combining CBD with warfarin requires increased INR monitoring. CBD inhibits CYP2C9, the primary enzyme that metabolizes S-warfarin. A case report (Grayson, Epilepsy & Behavior Case Reports, 2018) showed an increase in INR from 2.5 to 4.7 after the introduction of CBD and the need to reduce the warfarin dose by 30%. This decision rests with the treating physician, not the patient. Close monitoring of the INR is essential.

What happened to clobazam in the Devinsky study?

In the Devinsky 2017 study (NEJM) over Dravet syndrome in children taking CBD, an increase in the concentration of N-desmethylclobazam (the active metabolite of clobazam) by 300-500% was observed. This resulted in increased drowsiness and required a reduction in the clobazam dose in most patients. Mechanism: CYP2C19 inhibition by CBD (Epidiolex Prescribing Information, FDA, 2018).

Does CBD increase the risk of valproate hepatotoxicity?

Yes. In the Devinsky 2018 study on Lennox-Gastaut syndrome in 20% children combining CBD and valproate, ALT and AST increases above 3 times the normal range were observed (Epidiolex Prescribing Information, FDA, 2018). The hepatotoxic risk dictates mandatory liver function tests before starting and every four weeks during the first quarter of treatment. Any increase in transaminases requires consultation with the attending physician.

Does CBD affect the action of statins?

Yes, especially atorvastatin and simvastatin, which are metabolized primarily by CYP3A4. CBD may increase blood levels of these statins, increasing the risk of myopathy and rhabdomyolysis. Pravastatin and rosuvastatin are less dependent on CYP3A4, so the risk of interactions is lower (Brown & Winterstein, Journal of Clinical Medicine, 2019). Consultation with your family doctor or cardiologist is advisable before adding CBD to your treatment regimen.

Does CBD enhance the effects of benzodiazepines?

Yes. CBD and benzodiazepines (diazepam, lorazepam, alprazolam) depress the central nervous system. CBD also inhibits CYP3A4 and CYP2C19, increasing the concentrations of benzodiazepines metabolized through these pathways (Brown & Winterstein, Journal of Clinical Medicine, 2019). Effects: excessive drowsiness, impaired coordination, and rarely respiratory depression. Close medical supervision and possible reduction of the benzodiazepine dose are required.

How long do interactions last after stopping CBD?

CBD inhibition of CYP450 enzymes typically lasts 3-7 days after the last dose, and in individuals with high doses (above 300 mg per day) up to 10 days (Stout & Cimino, Drug Metabolism Reviews, 2014). Therefore, after discontinuing CBD therapy, the doses of drugs whose metabolism was inhibited should not be immediately increased. This decision is made by the physician based on monitored laboratory parameters.

Can I drink grapefruit juice with CBD?

Not recommended. Grapefruit juice inhibits CYP3A4 similarly to CBD. Combining both agents may synergistically increase concentrations of drugs metabolized by this pathway by 70-200% (FDA Consumer Update, 2017). If you are taking CBD and heart, immunosuppressive, or psychotropic medications, limit your consumption of grapefruit and bitter orange. Consult your pharmacist regarding the weekly intake limit.

Sources and scientific literature

Below, you'll find selected scientific and regulatory publications used to develop this guide. We recommend verifying specific interactions in current clinical databases (Lexicomp, Micromedex, KAMSOFT) and consulting your pharmacist or doctor before making any changes to your treatment.

• Devinsky O. et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine. 2017;376:2011-2020. NEJM
• Devinsky O. et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome. New England Journal of Medicine. 2018;378:1888-1897.
• FDA. Epidiolex (cannabidiol) Prescribing Information. 2018. accessdata.fda.gov
• Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metabolism Reviews. 2014;46(1):86-95. Tandfonline
• Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine. 2019;8(7):989. PubMed
• Grayson L. et al. An interaction between warfarin and cannabidiol, a case report. Epilepsy & Behavior Case Reports. 2018;9:10-11. PubMed
• Leino AD. et al. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. American Journal of Transplantation. 2019;19(10):2944-2948. PubMed
• FDA. Grapefruit Juice and Some Drugs Don't Mix. Consumer Update, 2017. FDA
• European Medicines Agency. Epidyolex – Summary of Product Characteristics. EMA

Related articles

To learn more about cannabinoids, their sources and how to use them, check out our related materials:

• Kosmos – Hemp CBDA ~6.5% – an acidic form of cannabinoid with a milder pharmacological profile
• Mars – CBD Hemp ~9% – herb with a standard CBD content for vaporization
• CBG and CBD – what is the difference? – a comparison of two key cannabinoids

This article is for informational and educational purposes only and does not constitute medical advice. Before using CBD for therapeutic purposes, consult your doctor or pharmacist, especially if you are taking other medications, are pregnant, breastfeeding, or treating a chronic condition. This guide does not replace individual clinical evaluation.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 26, 2026
Last update: April 26, 2026
Next review: April 26, 2027